[go: up one dir, main page]

RU2018125034A - BOTULOTOXIN FOR THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT WITH THE PARTICIPATION OF A NEUROMEDIATOR - Google Patents

BOTULOTOXIN FOR THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT WITH THE PARTICIPATION OF A NEUROMEDIATOR Download PDF

Info

Publication number
RU2018125034A
RU2018125034A RU2018125034A RU2018125034A RU2018125034A RU 2018125034 A RU2018125034 A RU 2018125034A RU 2018125034 A RU2018125034 A RU 2018125034A RU 2018125034 A RU2018125034 A RU 2018125034A RU 2018125034 A RU2018125034 A RU 2018125034A
Authority
RU
Russia
Prior art keywords
disorder
neurotransmitter
brain
violation
pain
Prior art date
Application number
RU2018125034A
Other languages
Russian (ru)
Other versions
RU2018125034A3 (en
Inventor
Гэри БОРОДИК
Мартин АКУАДРО
Original Assignee
Реванс Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/966,759 external-priority patent/US20160095908A1/en
Application filed by Реванс Терапьютикс, Инк. filed Critical Реванс Терапьютикс, Инк.
Publication of RU2018125034A publication Critical patent/RU2018125034A/en
Publication of RU2018125034A3 publication Critical patent/RU2018125034A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Claims (23)

1. Способ лечения расстройства центральной нервной системы, определяемого как наличие нарушения по меньшей мере одного нейромедиатора мозга по меньшей мере в одной или нескольких областях головного мозга, предусматривающий способ:1. A method of treating a disorder of the central nervous system, defined as the presence of a violation of at least one brain neurotransmitter in at least one or more regions of the brain, comprising a method: a. инъекции ботулотоксина во внечерепную область головы или шеи;a. injections of botulinum toxin into the extracranial region of the head or neck; b. таким образом, что внечерепная область головы и шеи находится в непосредственной близости с одной областью головного мозга с нарушенной активностью нейромедиатора, определенной при помощи ПЭТ-сканирования, функциональной магнитно-резонансной томографии или визуализации головного мозга;b. so that the extracranial region of the head and neck is in close proximity to one area of the brain with impaired neurotransmitter activity, determined by PET scanning, functional magnetic resonance imaging or brain imaging; c. при этом ботулотоксин блокирует нейропередачу, включающую по меньшей мере один нейромедиатор.c. while botulinum toxin blocks neurotransmission, including at least one neurotransmitter. 2. Способ по п. 1, где нейромедиатором является глутамат.2. The method of claim 1, wherein the neurotransmitter is glutamate. 3. Способ по п. 1, где нейромедиатором является ацетилхолин.3. The method of claim 1, wherein the neurotransmitter is acetylcholine. 4. Способ по п. 1, где нейромедиатором является ГАМК.4. The method of claim 1, wherein the neurotransmitter is GABA. 5. Способ по п. 1, где нейромедиатором является норадреналин.5. The method of claim 1, wherein the neurotransmitter is norepinephrine. 6. Способ по п. 1, где нарушение головного мозга ассоциировано с большим депрессивным расстройством.6. The method of claim 1, wherein the brain disorder is associated with major depressive disorder. 7. Способ по п. 1, где нарушение головного мозга ассоциировано с биполярным синдромом.7. The method of claim 1, wherein the brain disorder is associated with bipolar syndrome. 8. Способ по п. 1, где нарушение головного мозга ассоциировано с генерализованным тревожным расстройством и посттравматическим стрессовым расстройством.8. The method of claim 1, wherein the brain disorder is associated with generalized anxiety disorder and post-traumatic stress disorder. 9. Способ по п. 1, где расстройство связано с судорогами.9. The method of claim 1, wherein the disorder is associated with seizures. 10. Способ по п. 9, где судороги включают очаговый двигательный и парциальный комплекс.10. The method according to p. 9, where the convulsions include focal motor and partial complex. 11. Способ по п. 1, где расстройство представляет собой нейродегенерацию, характеризующуюся как болезнь Альцгеймера, болезнь Паркинсона или хорея Гентингтона.11. The method of claim 1, wherein the disorder is neurodegeneration characterized as Alzheimer's disease, Parkinson's disease, or Huntington's chorea. 12. Способ по п. 1, где расстройство представляет собой острое нарушение мозгового кровообращения.12. The method according to p. 1, where the disorder is an acute violation of cerebral circulation. 13. Способ по п. 1, где расстройство представляет собой гипертензию, опосредованную центральной нервной системой.13. The method of claim 1, wherein the disorder is hypertension mediated by the central nervous system. 14. Способ по п. 13, где расстройство включают нецентральный компонент эссенциальной гипертезии.14. The method of claim 13, wherein the disorder comprises an off-center component of essential hypertension. 15. Способ по п. 1, где расстройством является нарушение аппетита, которое представляет собой обсессивно-компульсивное расстройство.15. The method according to p. 1, where the disorder is a violation of appetite, which is an obsessive-compulsive disorder. 16. Способ по п. 1, где расстройство представляет собой нарушение циркадианного ритма.16. The method of claim 1, wherein the disorder is a circadian rhythm disorder. 17. Способ по п. 1, где расстройство представляет собой нарушение сна.17. The method of claim 1, wherein the disorder is a sleep disorder. 18. Способ по п. 1, где расстройство представляет собой болевой синдром, характеризующийся как мигрень, головная боль напряжения, комбинированная головная боль напряжения и мигрень, невралгия тройничного нерва, миофасциальная боль, кластерная головная боль, послеоперационная травматическая боль.18. The method of claim 1, wherein the disorder is a pain syndrome characterized as migraine, tension headache, combined tension headache and migraine, trigeminal neuralgia, myofascial pain, cluster headache, postoperative traumatic pain. 19. Способ по п. 1, где расстройство представляет собой шизофрению.19. The method of claim 1, wherein the disorder is schizophrenia. 20. Способ по п. 1, где расстройство представляет собой сезонное аффективное расстройство.20. The method of claim 1, wherein the disorder is a seasonal affective disorder.
RU2018125034A 2015-12-11 2016-12-09 BOTULOTOXIN FOR THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT WITH THE PARTICIPATION OF A NEUROMEDIATOR RU2018125034A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/966,759 US20160095908A1 (en) 2005-06-14 2015-12-11 Botulinum Toxin for Primary Disorders of Mood and Affect using Neurotransmitter CNS imaging Studies
US14/966,759 2015-12-11
PCT/US2016/065898 WO2017100624A1 (en) 2015-12-11 2016-12-09 Botulinum toxin for primary disorders of mood and affect using neurotransmitter

Publications (2)

Publication Number Publication Date
RU2018125034A true RU2018125034A (en) 2020-01-13
RU2018125034A3 RU2018125034A3 (en) 2020-04-15

Family

ID=59013649

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018125034A RU2018125034A (en) 2015-12-11 2016-12-09 BOTULOTOXIN FOR THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT WITH THE PARTICIPATION OF A NEUROMEDIATOR

Country Status (13)

Country Link
EP (1) EP3386538A4 (en)
JP (1) JP2019504824A (en)
KR (1) KR20180093983A (en)
CN (1) CN109069609A (en)
AU (1) AU2016366428A1 (en)
BR (1) BR112018011663A2 (en)
CA (1) CA3007816A1 (en)
CO (1) CO2018007096A2 (en)
IL (1) IL259825A (en)
MX (1) MX2018007105A (en)
RU (1) RU2018125034A (en)
SG (1) SG11201804840SA (en)
WO (1) WO2017100624A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021137667A1 (en) * 2019-12-30 2021-07-08 주식회사 에이티지씨 Composition for treating parkinson's disease containing botulinum neurotoxin, and method for treating parkinson's disease using same
GB202100566D0 (en) * 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
CN114384185A (en) * 2022-01-20 2022-04-22 北京航空航天大学 Application of reagent for detecting gamma-aminobutyric acid content in preparation of kit for diagnosing venous outflow obstruction diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609112B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
WO2005072433A2 (en) * 2004-01-26 2005-08-11 The Board Of Trustees Of The Leland Stanford Junior University Toxin induced sympathectomy
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US7655244B2 (en) * 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20070218084A1 (en) * 2005-12-30 2007-09-20 Fondazione Pierfranco E Luisa Mariani- Onlus Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
CA2661220A1 (en) * 2006-08-21 2008-02-28 James R. Hauske Multimediator transporter inhibitors for use in treatment of central nervous system disorders
JPWO2010013495A1 (en) * 2008-07-31 2012-01-05 一般財団法人化学及血清療法研究所 Pharmaceutical composition containing highly purified botulinum toxin therapeutic agent as active ingredient and use thereof
US9393291B2 (en) * 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations

Also Published As

Publication number Publication date
KR20180093983A (en) 2018-08-22
CN109069609A (en) 2018-12-21
EP3386538A1 (en) 2018-10-17
EP3386538A4 (en) 2019-07-17
AU2016366428A1 (en) 2018-06-28
BR112018011663A2 (en) 2018-12-04
CO2018007096A2 (en) 2018-11-22
MX2018007105A (en) 2018-09-07
IL259825A (en) 2018-07-31
WO2017100624A1 (en) 2017-06-15
CA3007816A1 (en) 2017-06-15
JP2019504824A (en) 2019-02-21
SG11201804840SA (en) 2018-07-30
RU2018125034A3 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
Faggiani et al. Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: From history to the interaction with the monoaminergic systems
RU2018125034A (en) BOTULOTOXIN FOR THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT WITH THE PARTICIPATION OF A NEUROMEDIATOR
Slattery et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review
Kerestes et al. Functional brain imaging studies of youth depression: a systematic review
Laxpati et al. Deep brain stimulation for the treatment of epilepsy: circuits, targets, and trials
Titov et al. Disorder-specific versus transdiagnostic and clinician-guided versus self-guided treatment for major depressive disorder and comorbid anxiety disorders: a randomized controlled trial
Firouzabadi et al. Effectiveness of detached mindfulness techniques in treating a case of obsessive compulsive disorder.
Bunse et al. Motor cortical excitability assessed by transcranial magnetic stimulation in psychiatric disorders: a systematic review
Blázquez et al. Cognitive and emotional profiles of aged Alzheimer's disease (3× TgAD) mice: effects of environmental enrichment and sexual dimorphism
ECSP19048477A (en) BICYCLE INHIBITORS [1.1.1] DUAL LEUCINE ZIPPER KINASE PENTANE (DLK) FOR THE TREATMENT OF DISEASES
EA201300975A1 (en) NEW COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
CO2021002087A2 (en) Method to treat epilepsy
EA201792437A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH AGING
CO2019002839A2 (en) Dual leucine zipper (dlk) kinase inhibitors for the treatment of diseases
EA201691602A1 (en) COMBINATION OF BACLOPHENE, ACAMPROSATE AND MEDIUM-NECK TRIGGYCERIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
Parain et al. Large-field repetitive transcranial magnetic stimulation with circular coil in the treatment of functional neurological symptoms
IL313097A (en) Methods for treating central nervous system disorders
EP3943107A4 (en) COMPOSITION FOR PREVENTING OR TREATING DISEASE OF THE BRAIN AND NERVOUS SYSTEM
MX385967B (en) METHOD FOR THE RAPID MATURATION OF DISTILLED ALCOHOLS USING LIGHT AND HEAT PROCESSES.
MX2010010233A (en) Novel compounds advantageous in the treatment of central nervous system diseases and disorders.
JP2014500885A5 (en)
WO2014111525A3 (en) Combination therapies for treating nervous system diseases
EP4446417A4 (en) CORYNEBACTERIUM GLUTAMICUM VARIANT WITH IMPROVED L-LYSINE PRODUCTIVITY AND METHOD FOR THE PRODUCING OF L-LYSINE WITH IT
RU2016152150A (en) Botulinum toxin for use in the treatment of paratonia
SUN et al. Clinical effect and electroencephalographic oscillation changes of the repetitive transcranial magnetic stimulation and eszopiclone treatment of chronic insomnia disorder

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20211203